Chinese continuous glucose monitor developer Zhejiang POCTech Medical has raised $14.5 million in a Series B round of financing, according to a Deal Street Asia report.
The round was led by Bioventure Investment Management and Tasly Great Health Industry Fund and joined by Tonghua Dongbao Pharmaceutical Co and previously vested Legend Capital.
POCTech produces the CT-100 continuous glucose monitoring system designed for patients with Diabetes, along with other diabetes products.
The company has already obtained CE Mark approval in the European Union, according to a Deal Street Asia report.
